pravastatin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases total cholesterol (TC)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“Pravastatin use was associated with a significantly greater decrease from baseline to week 6 and baseline to week 12 in LDL cholesterol (Week 6 – Baseline ANCOVA: p<.0001 and Week 12 – Baseline ANCOVA: p=0.0003), total cholesterol (Week 6 – Baseline ANCOVA: p<0001 and Week 12 – Baseline ANCOVA: p=0.001), and small LDL particle numbers (Week 6 – Baseline ANCOVA: p= 0.05 and Week 12 – Baseline ANCOVA: p=0.009).”
Quoted verbatim from A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.. - Study
- RCT
- Duration
- 3 months
- Dose
- 40 mg/day
- Population
- Outpatients aged 18 to 68 with schizophrenia or schizoaffective disorder on stable antipsychotic treatment; change from baseline to week 12
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.2014PMID:25261882Permalink
Keep reading
- Everything the graph holds on pravastatin
- Every compound studied against Total cholesterol (TC)
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PR9DZVJW3T2E7YWJ3HNFT9